
|Articles|January 1, 2004
Combination kills cancer
New York - Results from the largest-ever phase III trial in advanced metastatic melanoma, while preliminary, suggest dacarbazine (DTIC) plus an investigational antisense compound (oblimersen sodium, or Genasense) may significantly improve overall survival versus DTIC alone, according to Anna C. Pavlick, D.O.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Clinicians Weigh Topical Sequencing and Escalation in Complex Atopic Dermatitis Cases
2
Phase 3 STOP-HS Trials Highlight Promise of Oral JAK1 Inhibition for Moderate to Severe Disease
3
Sonelokimab Meets Primary End Point in Phase 3 Psoriatic Arthritis Trial
4
Common Mistakes in Managing Hair Loss and Pigmentary Disorders
5











